对肝素相关性血小板减少症具有治疗价值。
The medicine composition has value of curing the heparin-induced thrombocytopenia.
这是一种新的血小板生成剂治疗儿童免疫性血小板减少症（ITP）的首例研究成果。
This is the first publication of the results of one of the new thrombopoietic agents in the treatment of children with immune thrombocytopenia (ITP).
目的探讨脾脏射频消融术治疗顽固性免疫性血小板减少症(itp)的安全性和有效性。
Objective to assess the safety and efficacy of radiofrequency ablation of the spleen for intractable immune thrombocytopenia (ITP).
本发明提供了一种治疗肝素相关性血小板减少症的药物组合，其主要成分包括可接受药物量的重组水蛭素及其医药上可接受的盐。
The invention provides a medicine composition for curing heparin-induced thrombocytopenia. The main components include Lepirudin and salt which can be accepted by the medicine.
静息性的肝硬化可能在出现因门脉高压引起的充血性脾肿大导致的无症状的血小板减少症之后才被发现。
Silent cirrhosis may be discovered after the finding of asymptomatic thrombocytopenia caused by the congestive splenomegaly of portal hypertension .
方法需行脾切除术的患者2 0例，包括肝硬化继发性脾亢4例，脾假性囊肿1例，遗传性球形细胞增多症1例，原发性血小板减少性紫癜14例。
Methods 20 cases underwent splenectomy, including 4 cases of hypersplenism secondary to hepatic cirrhosis, 1 case of pseudocyst of spleen, 14 cases of primary thrombocytopenic purpura.
方法需行脾切除术的患者2 0例，包括肝硬化继发性脾亢4例，脾假性囊肿1例，遗传性球形细胞增多症1例，原发性血小板减少性紫癜14例。
Methods 20 cases underwent splenectomy, including 4 cases of hypersplenism secondary to hepatic cirrhosis, 1 case of pseudocyst of spleen, 14 cases of primary thrombocytopenic purpura.
应用推荐